PARP inhibitors have become an integral component of treatment strategies for advanced epithelial ovarian cancer, particularly in BRCA1/2-mutated and homologous recombination-deficient (HRD) tumors. Despite clinically meaningful improvements in progression-free survival, a substantial proportion of patients develop pri...
D. Incognito, G. Ciappina, G. Ettore et al.· Frontiers in Oncology· 0 citations
This review provides a comprehensive, updated, and comparative overview of PIK3CA biology, its molecular alterations across human cancers, their prognostic and therapeutic relevance, and the current development of treatments targeting the pathway activated by PIK3CA.
A. Ottaiano, C. Picone, M. Santorsola et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.